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Abstract
Background: Th17 cells play a major role in coordinating the host defence in oropharyngeal candidiasis. In this study we
investigated the involvement of the Th17 response in an animal model of vulvovaginal candidiasis (VVC).
Methods: To monitor the course of infection we exploited a new in vivo imaging technique.
Results: i) The progression of VVC leads to a strong influx of neutrophils in the vagina soon after the challenge which
persisted despite the resolution of infection; ii) IL-17, produced by vaginal cells, particularly CD4 T cells, was detected in the
vaginal wash during the infection, reaching a maximum 14 days after the challenge; iii) The amount and kinetics of IL-23 in
vaginal fluids were comparable to those in vaginal cells; iv) The inhibition of Th17 differentiation led to significant inhibition
of IL-17 production with consequent exacerbation of infection; v) An increased production of bdefensin 2 was manifested in
cells of infected mice. This production was strongly reduced when Th17 differentiation was inhibited and was increased by
rIL-17 treatment.
Conclusions: These results imply that IL-17 and Th17, along with innate antimicrobial factors, have a role in the immune
response to vaginal candidiasis.
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Introduction
Candida vulvovaginal infection is a frequent and common
distressing disease affecting 70%–75% of women of childbearing
age worldwide at least once during their lifetime. 5%–10% of
women with a primary episode of VVC subsequently experience
frustrating recurrent infection (RVVC) [1], defined as at least
three-four specific episodes within one year [2,3]. There are two
forms of RVVC: primary RVVC is idiopathic with unknown
predisposing factors, secondary RVVC is the occurrence of
frequent episodes of acute VVC because of certain predisposing
factors such as hormone replacement therapy or diabetes mellitus
[4].
It has been demonstrated that the vaginal mucosa, its tissue
structure and cervicovaginal fluids, contains both humoral and
cellular components of innate and acquired immune responses [5].
Animal models are frequently used to evaluate host defense
mechanisms against Candida vaginitis [6]. Candida albicans is not a
natural colonizer of the vaginal mucosa but the use of estrogen
favors a persistent infection and this can be exploited in order to
study the immune response [4,5]. The mouse infection model has
many advantages, such as its similarity with the human infection
and the possibility of performing vaginal lavages to quantify the
fungal burden. The major disadvantages are the requirement for a
condition of pseudo-estrus induced by estrogen, the neutral vaginal
pH, and the lack of symptoms [6].
The Th1 response has been shown to be induced in the systemic
draining lymph nodes of vaginally infected mice, but does not
protect against the infection [7]. Despite the evidence reported for
competent vaginal cell-mediated immunity, resident T cells,
during infection, appeared to have little or no protective role
[8,9,10,11,12,13].
Th17 cells belong to a lineage different from that of Th1 and
Th2 cells, and they are characterized by the production of IL-17A,
IL-17F and IL-22 [14]. The protective action of IL-17 against
extracellular pathogens also involves neutrophil recruitment to the
infection sites [15]. IL-17 has a central role in protective immunity
against C. albicans systemic and oral infections [16,17,18]. In
response to a systemic challenge with C. albicans, IL-17AR-
deficient mice showed a reduced survival rate and a significant
increase of kidney fungal burden. Mobilization and influx of
neutrophils to infected organs were also impaired and delayed
[16]. In another study, the Th17 response also conferred
protection against oropharyngeal candidiasis through neutrophil
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present work, we focus on the role of IL-17 in protecting against
vaginal candidiasis, exploiting a new in vivo imaging technique
that we have recently developed [19,20]. In the in vivo imaging
method a C. albicans strain is used that expresses a cell surface
luciferase constructed by fusing the Gaussia princeps luciferase to the
C. albicans PGA59 glycosylphosphatidylinositol-linked cell wall
protein [19]. This technique allows continuous, non-invasive
monitoring of the spatial and temporal progression of vaginal
infection in live mice and has proved useful to evaluate vaccinal
and immunotherapeutic approaches to the treatment of vaginal
candidiasis [20].
Results
Th17 response in murine vaginal infection by Candida
albicans
We investigated the role of Th17 during vaginal candidiasis
using CD1 female mice maintained under pseudo-estrus condi-
tions and vaginally infected with the pathogenic C. albicans
gLUC59 strain as previously reported [19]. gLUC59 has been
used to monitor the course of different types of C. albicans infection.
Studies performed on mice infected with C. albicans strain CA1398
carrying the ACT1p-gLUC fusion (gLUC59), or the control strain
CA1399 which did not express gLUC59, showed that these
gLUC59 and control strains were equally pathogenic [19]. Data
presented in Figure 1 show that significant luminescence signals,
obtained following injection of the luciferase substrate coelenter-
azine in the vagina and animal imaging using the Xenogen IVIS-
200
TM imaging system, were evident after 4 days of infection and
declined after day 18 post-infection (Fig. 1B). The analysis of the
total photon emission showed a significant reduction of the fungal
load from day 20 post-infection; a similar trend was observed by
CFU counting from vaginal lavages from the same mice (Fig. 1C).
Analysis of the two parameters measured to estimate the fungal
burden, photon emission and CFUs, showed a good correlation
between the results obtained with the two methods, for all
experimental time points (Fig. 1D)
In selected experiments, a histological analysis of the vagina was
performed and the cellular composition of the vaginal fluid was
examined. Results reported in Fig. 2A show that different cell
types were present in the vaginal fluid of infected mice, especially
neutrophils and epithelial cells. In uninfected mice, mainly
epithelial and, rarely, immune cells, were detected. The trend of
the cellular influx in the vagina of infected mice was evaluated by
cytofluorimetric analysis (Fig. 2B) showing that, 48 h post-
infection, a massive infiltration of neutrophils was evident (75%
of total cells). Subsequently, the level of neutrophils decreased to
about 60% of the total cells, a level that was maintained until the
monitoring of the Candida infection finished (Fig. 2B). The
histological analysis performed on day 1 post-infection evidenced
that intraepithelial microabscesses consisting of polymorphonucle-
ar cells were only present in the vagina of infected mice (Fig. 2C).
Moreover a massive presence of fungal hyphae with rare
blastospores was observed in the vaginal lumen and in the
superficial epithelial layer until day 22 post-infection (Figure 2C).
Because it has been demonstrated that IL-17 has a critical role
in protecting against mucosal, particularly oropharyngeal, candi-
diasis [17], we investigated the presence of this cytokine in our
model of vaginal infection. Results reported in Figure 3A
demonstrate that there is an early production of IL-17, starting
48 h after the challenge, reaching a maximum 14 days post-
infection, and subsequently decreasing to return to basal levels
after 5 weeks of infection. The early production of IL-17 in the
vaginal wash could presumably be attributed to PMN and
epithelial cells, which are known to be innate system cells capable
of producing IL-17 [21]. We also performed experiments using
lower doses of C. albicans. The results showed that inocula of 10
7,
5610
6 or 10
6 are also able to induce IL-17 production (Fig. 3B). In
a parallel experiment we evaluated the ability of the control strain
of C. albicans CA1399 to induce IL-17 production. All concentra-
tions of inocula used in the experimental vaginal infection induced
cytokine production at day 14 (Figure 3C), as did the gLUC59
strain. It has been reported that elicitation of the IL-17 response
correlated with the ability of C. albicans hyphae to stimulate
antigen-presenting cells for the priming of Th-17 responses in vitro
and for the production of IL-23, but not IL-12 [22]. IL-23 induces
the differentiation of naive CD4(+) T cells into helper T cells that
produce IL-17 [23]. Moreover, IL-23 appears to induce IL-17, IL-
1 and IL-6 production from cells of the innate immune system
[24]. Given this premise, we analyzed IL-23 levels in the
intravaginal lumen. Results reported in Figure 3D show the
presence of IL-23 in the vaginal wash of infected mice. An
increased production of this cytokine was manifested 24 h after the
challenge, reaching a maximum at 48 h, declining from day 3–10
post-infection and then increasing until the end of the monitoring.
Importantly, IL-23 was recovered in vaginal fluids of infected mice
at all time points except day 14 post-infection (Fig. 3D).
Role of vaginal and lymph node cells in Th-17 response
In selected experiments the vagina and the lumbar lymph nodes
from both infected and non infected mice were removed and
vaginas were treated with collagenase. Results reported in
Figure 4A demonstrate that IL-17 was produced by vaginal cells
recovered from infected mice and that production reached a
maximum 15–22 days post-infection, then declining. In a parallel
analysis the production of IL-23 was tested in the same
supernatants. Kinetic analysis showed a significant increase of
IL-23 levels at day 4, which declined in the following days (Fig. 4B).
A similar trend for IL-17 and IL-23 production was observed
when vaginal cells were re-stimulated with heat-inactivated yeasts.
To study the phenotype of cells producing IL-17, cells cultivated
for 72 h were recovered, fixed, and labeled for Gr-1 or CD4
receptors. Intracellular IL-17 expression was evaluated in CD4 T
cells and neutrophils, which are the major IL-17 producing cells.
In our experimental conditions CD4 positive cells appeared the
main source of IL-17, with maximum intracellular expression
between days 8 and 21 (Fig. 4C). Yet some Gr-1 positive cells
(neutrophils) also had appreciable levels of IL-17 intracellular
expression seven days post infection (Fig. 4D).
Draining lymph nodes were also removed, cultivated for 72 h,
then either left untreated, or stimulated with heat inactivated C.
albicans, and the supernatant fluids were tested for the presence of
IL-17 and IL-23. The results in Figure 5A show that IL-17 was
produced by lymph nodes 22 days post-infection. After stimulation
in vitro lymph node cells produced significant levels of IL-17 even
at day 8, suggesting that some cells were already activated. A
significant increase in IL-23 production was manifested 7 days
after infection reaching a maximum at day 22 (Figure 5B). A
similar trend was observed when cells were re-stimulated with heat
inactivated Candida cells.
Role of Th17 in vaginal Candida infection
Recently it has been demonstrated that halofuginone is a
specific potent inhibitor of mouse and human Th17 differentiation
[25]. To analyze the role of Th17 response in our experimental
model of vaginal candidiasis we treated mice with halofuginone
every two days, starting two days before the infection (Fig. 1A).
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times after infection showed that the halofuginone treatment at a
dose of 5 mg/mouse significantly lowered IL-17 production from
day 6 to day 21. A dose of 10 mg/mouse completely suppressed IL-
17 production (Fig. 6A). In addition, the fungal load evaluated
from the bioluminescence intensity was found to be significantly
higher in halofuginone treated mice (5 mg/mouse) with respect to
diluent treated mice (Fig. 6B). This was correlated to a significant
increase of CFU (507% fourteen days after infection and 208%
twenty-five days after infection) in the vaginal wash of halofugi-
none treated mice (Fig. 6C). In further experiments, mice were
treated with a higher dose of halofuginone (10 mg/mouse). In this
case the increase of CFU was of 608% fourteen days after infection
and 462% twenty-five days after infection. In parallel experiments
the IL-17 depletion due to halofuginone treatment was restored by
intravaginal administration of mouse recombinant IL-17 every 2
days. The fungal load was monitored 4, 8 and 14 days post
infection. The bioluminescence and the CFU in rIL-17 treated
mice were similar to those observed in the diluent treated mice
used as a control group, and not statistically significant (Fig. 7A).
Antimicrobial peptides have an important role in the innate
immune response of host cells [21] and are secreted particularly by
vaginal epithelial cells [26,27,28]. We analyzed the kinetics of b-
defensin 1, 2 and 3 (BD-1, BD-2 and BD-3, respectively) level in
Figure 1. Model of murine vaginal infection and monitoring. (A) Timeline of vaginal infection model. CD1 mice are resistant to Candida
vaginal infection unless they are treated with estradiol valerate. CD1 mice were treated subcutaneously with estradiol valerate and infected for two
consecutive days with 10 mlo f1 0
9/ml suspension of Candida albicans cells (gLUC) into vaginal lumen. Two days before and every two days after
challenge mice were treated intraperitoneally with halofuginone or diluent of halofuginone and, in selected experiments, intravaginally with 10 pgo f
recombinant mouse IL-17. After 4, 8, 12, 14, 18, 20, 25, 30 days post infection, mice were treated intravaginally with 10 mg of coelenterazine and
imaged in the IVIS-200
TM imaging system under anaesthesia using 2.5% isoflurane and the vaginal lumen was washed with 150 ml of saline using
mechanical pipette. The fungal burden of vaginal fluids was evaluated by colony forming units (CFU) assay. (B) In vivo imaging of mice vaginally
infected with Candida albicans cells (gLUC). Images are representative of 5 out of 10 mice for each experiment. C) Dot plots of total photon emission
from the infected vaginal regions and corresponding CFU in vaginal washes of infected mice (n=10). The statistical analysis was performed by non-
parametric Mann-Whitney U test. The median is indicated by a straight line. Data are representative of one of two independent experiments with
similar results. D) The correlation between the Total Photons emitted and CFU count in the vaginal wash was assessed using the Pearson’s correlation
statistics, and the correlation coefficients are shown for each time point. * p,0.05, ** p,0.01, (Log Photons Total Flux or Log CFU/ml of mice infected
after 8, 12,14,18,20,25,30 days vs Log Photons Total Flux or Log CFU/ml of mice infected after 4 days).
doi:10.1371/journal.pone.0022770.g001
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reported in Figure 7B demonstrate that halofuginone treatment
produced a significant down-regulation of the production of BD-2
at day 14 and 21 (p,0.01). In contrast, intravaginal administration
of rIL-17 together with halofuginone restored defensin production
at day 14 and 21 (p,0.01). BD-1 was not produced. BD-3 was
produced 2 and 7 days post infection, and halofuginone was also
able to down regulate the production of this peptide. Moreover,
the administration of recombinant IL-17 was able to restore the
production of the antimicrobial factor. The cytofluorimetric
analysis of cells recovered from the vaginal washes showed that
the BD2 was produced by epithelial cells (Figure 7C). The
increment of b-defensin 2 and 3 production after rIL-17 treatment
of halofuginone treated mice correlated with a more rapid
clearance of C. albicans (data not shown).
Discussion
Mouse models of mucosal candidiasis, including gastrointestinal,
oropharingeal and vaginal candidiasis, have provided an invalu-
able contribution to the understanding of the local immune
response to C. albicans.
In this study we investigated Th17 responses during vaginal
candidiasis and demonstrated that i) vaginal candidiasis leads to a
strong influx of neutrophils to the vagina; 75% of the cells present
in the vaginal wash soon after the challenge are neutrophils, a
percentage which decreased to 60% until the resolution of
infection; ii) IL-17 was detected during infection in vaginal fluids,
its production reaching a maximum 14 days after the challenge
and subsequently decreasing; iii) IL-17 was produced by CD4 T
cells in particular, and there was a correlation between the
presence of vaginal IL-17 and fungal burden; iv) an appreciable
level of IL-23 was observed in the vagina and the amount and
kinetics of IL-23 in vaginal fluids were comparable to those in
vaginal cells; v) the inhibition of Th17 differentiation leads to
significant inhibition of IL-17 production, with consequent
exacerbation of infection; and vi) production of beta defensin 2
and beta defensin 3 was manifested in cells of infected mice, this
production being strongly reduced when Th17 differentiation was
inhibited and stimulated by rIL-17 treatment. Taken together,
Figure 2. Polymorphonuclear cell influx in murine vaginal compartment of mice infected with Candida albicans. (A) Vaginal fluids
obtained from Candida infected (left) and non infected (right) mice at day 2 post-infection were cytospun onto glass slides, air dried, stained using
Diff Quick coloration, and analyzed by light microscope (magnification,640). (B) Percentage of polymorphonuclear cells present in vaginal washes of
Candida infected mice and non infected mice at different times after infection. The cells present in vaginal lavages obtained by centrifugation of the
total vaginal wash were stained with a polymorphonuclear cell antibody (anti mouse Ly-6G-FITC) and analyzed by FACS machine. Results are
expressed as mean6SD (n=12 mice, 4 mice for each of three separate experiments). (C) Histological evaluation of vaginal Candida albicans infection.
At day 1,7, 22 and 30 after infection, five sections of vagina per mouse from two mice per group (above, non infected mice; below, infected mice)
were stained with period acid-Schiff reagent and viewed (magnification, 610 and 640; bars 50 mm and 200 mm respectively). The pictures are
representative of one of two independent experiments with similar results.
doi:10.1371/journal.pone.0022770.g002
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protecting against vaginal candidiasis, possibly through their
influence on antimicrobial peptide production by vaginal epithelial
cells.
Here we demonstrate that the course and resolution of vaginal
infection is strictly correlated to the presence of IL-17 secreted
locally by CD4 vaginal T cells. This is consistent with a report
showing that vaginal T cells have been characterized and
quantified in the lamina propria and the epithelia of the vagina
and cervix. It has been estimated that there are about 240 T
lymphocytes per mm
2 of vaginal epithelial tissue [29] and it is
conceivable that the majority of vaginal T cells migrate to the
vaginal epithelium in response to inflammatory chemokines
following local antigenic stimulus. This increase of IL-17 in the
vaginal wash mirrored the kinetics of IL-17 production by CD4
vaginal cells, however Gr-1 positive cells showed a marginal
production of IL-17 too. It is conceivable that an early presence of
IL-17 could be due to neutrophils and epithelial cells. This is
consistent with previous research showing that IL-17 is also
produced by neutrophils [30] and epithelial cells [21]. It is
noteworthy that the level of IL-23 was modest with respect to IL-
17, in all determinations performed. In addition, the seeming
independence of IL-17 from IL-23 could be due to prompt
reutilization of IL-23 by T cells. Alternatively, expansion of Th17
cells could occur, even when IL-23 levels are low, as has been
described in other experimental models [31].
Halofuginone, a low molecular weight derivative of the plant
alkaloid febrifugine, is able to inhibit collagen a1 gene expression in
several animal models of fibrosis and cancer [32,33,34]. Recently, it
has been reported that halofuginone inhibits transforming growth
factor-b (TGF- b) signaling [33] which is known to drive
differentiation of Th17 cells in the mouse. It has recently been
reported that halofuginone induces selective inhibition of Th17
differentiation and does not influence Th1, Th2, or Treg
differentiation [25]. In our experimental system the infection was
exacerbated and IL-17 secretion was inhibited by halofuginone
treatment. Compelling evidence revealed a critical role for IL-17 in
the induction of natural immune genes, including antimicrobial
peptides such as defensins, S100, mucins, etc [35,36,37,38]. In our
experimental system beta defensin 1 was not recovered in the
vagina, conversely a strong increase of b2 defensin and a significant
increase of beta 3 defensin were manifested during the infection.
Halofuginone treatment, which strongly impaired IL-17 secretion,
also caused a significant decrease of beta defensin 2 and 3. The
direct relationship between the presence of IL-17 and beta defensin
2 and 3 was also corroborated by the drastic increase of beta
defensin 2 after treatment with rIL-17.
Th17 responses have been shown to be involved in the
protective response against fungal and bacterial mucosal infections
[39,40,41]. Current literature attributes a critical role in neutrophil
recruitment to IL-17 [42]. In a mouse model of systemic
candidiasis a protective role was attributed to IL-17 because of
its ability to induce neutrophil recruitment [18]. The mechanism
by which Th17 immunity leads to resistance to OPC involves both
IL-17-induced neutrophil recruitment and direct IL-17-induced
antimicrobial effects. In our system the increase of IL-17 in the
Figure 3. IL-17 and IL-23 concentration in murine vaginal
washes of mice infected with Candida albicans. Evaluation of IL-17
(A–C) and IL-23 (D) concentration by ELISA test on supernatants of
vaginal fluids obtained at different times after vaginal infection with
different doses of Candida albicans gLUC59 (A–B) or CA1399 (D). Results
are expressed as mean6SD (n=12 mice, 4 mice for each of three
separate experiments). * p,0.05, (infected mice vs non infected mice).
doi:10.1371/journal.pone.0022770.g003
A Protective Role for IL-17 in Candida Vaginitis
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22770vaginal lumen and its secretion by vaginal cells seems to be
independent of the neutrophil influx. As a matter of fact the robust
early neutrophil migration observed soon after infection (Fig. 2)
seems mainly attributable to chemotactic molecules, produced by
epithelial cells following interaction with C. albicans [38]. Indeed
the level of neutrophils also remained high during the resolution of
infection, while the IL-17 production paralleled the course of
infection. Given that a correlation between infiltration of
polymorphonuclear neutrophils and symptomatic vulvovaginal
candidiasis has been observed [43], the lack of correlation between
the presence of IL-17 and neutrophil infiltration suggests the role
of IL-17 may be to protect from, rather than to participate in, the
inflammatory response.
As previously reported, we observed a massive influx of
neutrophils to the vagina [10]. These cells were unable to inhibit
the growth of C. albicans yeast and hyphae formation, despite their
primary role as anti-Candida effector cells. There are two possible
explanations for this inefficiency in the neutrophil performance:
one is that the neutrophil influx occurred when the yeast-mycelial
transition had already finished, the second is that neutrophils, due
to microenvironmental conditions, are unable to inhibit Candida
growth in the vaginal compartment.
Epithelial cells could indeed strongly contribute to Candida
clearance [44,45] and vaginal epithelial cells are described as
having an important role in retarding or arresting C. albicans
growth in a non inflammatory manner [46].
Our results show for the first time that a robust Th17 response is
found to occur in the vagina during vaginal candidiasis, and IL-17
plays a role in controlling C. albicans infection as it induces vaginal
epithelial cells to produce antimicrobial peptides.
Materials and Methods
Ethics Statement
All animal experiments adhered to the EU Directive 86/609.
Experiments were performed according to the guidelines of the
Figure 4. Effect of Candida albicans infection on vaginal cells. Vaginal cells were obtained at different times after vaginal Candida infection by
collagenase digestion of whole vaginas aseptically recovered. Evaluation of IL-17 (A) and IL-23 (B) concentration by ELISA on supernatant fluids of
72 hour vaginal cells culture. Results are expressed as mean6SD (n=16 mice, 4 mice for each of four separate experiments). The statistical analysis
was performed by Mann-Whitney U test. * p,0.05 (cells from infected mice vs cells from non infected mice), # p,0.05 (vaginal cells re-stimulated
from infected mice vs vaginal cells re-stimulated from non infected mice). Ratio between CD4-IL-17 positive cells (C) and between IL-17 positive Gr-1
positive cells (D) present in whole vagina of Candida infected mice and those present in the vaginas of non infected mice. The vaginal cells were
stained with anti mouse CD4-FITC or a monoclonal antibody to mouse Gr-1 molecule expressed by neutrophils and with anti mouse IL-17-PE
conjugate antibody for 45 minutes. After this they were analyzed by FACS machine. Results are expressed as mean6SD (n=12 mice, 4 mice for each
of three separate experiments).
doi:10.1371/journal.pone.0022770.g004
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used for Experimental and other Scientific Purposes. (ETS
No. 123). The protocol was approved by Perugia University
Ethics Committee (Comitato Universitario di Bioetica) (permit
numbers 41-2005B and 34/2003-A). All efforts were made to
minimize suffering during experiments.
Microorganisms
In this study a novel reporter system for imaging Candida albicans
infections was used. This luciferase reporter was constructed by
fusing a synthetic codon-optimized version of the Gaussia princeps
luciferase gene to PGA59 gene of C. albicans (strain CA1398), which
encodes a glycosylphosphatidylinositol-linked cell wall protein,
under the control of ACT1 promoter [19]. For experimental
infections, cells from stock cultures in YPD agar with chloram-
phenicol (1% yeast extract, 2% peptone, 2% glucose, all w/v) were
grown in YPD medium for 24 h, then harvested by centrifugation,
washed and counted as previously described [20] in an
hemocytometer, and resuspended to the desired concentration in
sterile physiological saline. Candida albicans cells were inactivated by
heating at 60uC for 30 minutes.
Mice
Female CD1 mice obtained from Harlan Italy Laboratories
(Udine, Italy) were used at seven weeks of age. Mice were allowed
to rest for 1 week before the experiment; by that time the animals
were roughly 8 weeks old.
Animal model of vaginal infection
The mouse model of vaginal infection has been described
previously [19,20]. Six days prior to infection a pseudo-estrus
condition was induced in mice by subcutaneous injection of
0.2 mg of estradiol valerate in 100 ml of sesame oil (Sigma-
Aldrich); this was repeated weekly until the completion of the
study. Mice anesthetized with 2.5 (v/v) isoflurane gas were infected
twice at a 24 h interval with 10 mlo fa1 0
9/ml, 5610
8/ml or 10
7/
ml of C. albicans cell suspensions administered by mechanical
pipette into the vaginal lumen, close to the cervix. Following
infection the fungal burden was monitored by an in vivo imaging
system and by analysis of the vaginal wash (Figure 1A).
Monitoring of mouse vaginal infection
To monitor the course of infection, at selected days post-
infection (starting 4 days after the challenge), 10 ml (0.5 mg/ml in
1:10 methanol:H20) of coelenterazine (Synchem, OHM) were
added to the vaginal lumen. Afterwards, mice were imaged in the
IVIS-200TM imaging system under anaesthesia using 2.5%
isoflurane. Total photon emission from vaginal areas within the
images of each mouse was quantified as previously described
[19,20]. The vaginal lavages were conducted using 150 ml of saline
with repeated aspiration for 10 to 20 times and the fluid was
serially diluted and plated on YPD agar plus chloramphenicol.
CFU were then evaluated and expressed as CFU/ml.
Vaginal cell collection and processing
The vaginal washes obtained at different days after infection
were treated with protease inhibitors (Complete Protease Inhibitor
Cocktail, Sigma-Aldrich) and centrifuged. After centrifugation at
6006g the supernatants were recovered and stored at 220uC and
the cells of the vaginal wash were fixed with 4% of PFA. To
analyze the polymorphonuclear cell number in the vaginal wash
the cells were incubated with rat anti-mouse Ly6G FITC
conjugate for 45 minutes on ice. Labelled cells were analyzed by
a cytofluorimeter. The cells were first analyzed using FSC/SSC
parameter and polymorphonuclear cells were gated according to
their size and granularity, then gated cells were tested for Ly6G
expression.
After vaginal infection, at different time points, the vaginas were
aseptically removed from dead mice; the vaginal tissue was cut
longitudinally and minced with sterile scalpel in cRPMI medium
consisting of RPMI 1640 supplemented with 10% heat-inactivated
fetal calf serum and 100 ml/ml penicillin streptomycin (Gibco).The
tissues were digested with cRPMI supplemented with sterile 0.25%
collagenase from Clostridium histolyticum (Sigma-Aldrich), following
incubation for 30 minutes at 37uC [47]. After digestion, tissues
and cells were filtered with a cell strainer 100 mm (BD Falcon) and
Figure 5. Effect of Candida albicans infection on draining lumbar lymph nodes. Lymph nodes, at different times after Candida infection,
were aseptically recovered and mechanically homogenized. Cells were cultivated untreated or in presence of heat inactivated C. albicans for 72 hours.
In the supernatant fluids of lymph node cell culture IL-17 (A) and IL-23 (B) were analyzed by ELISA. Results are expressed as mean6SD (n=16 mice, 4
mice for each of four separate experiments). The statistical analysis was performed using Mann-Whitney U test. * p,0.05, (Lymphocytes from infected
mice vs Lymphocytes from non infected mice). # p,0.05, ## p,0.01, (Lymphocytes re-stimulated from infected mice vs Lymphocytes re-stimulated
from non infected mice).
doi:10.1371/journal.pone.0022770.g005
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7 Candida albicans in
vagina. Two days before and every two days after infection, mice were injected intraperitoneally with 5 mg/100 mlo r1 0mg/100 ml of halofuginone
solution or diluent of halofuginone and, in selected experiments, were treated intravaginally with 10 pg of mouse rIL-17. (A) Evaluation of IL-17
concentration by ELISA in supernatants of vaginal fluids obtained at different days after vaginal Candida infection and halofuginone treatment.
Results are expressed as mean6SD (n=9 mice, 3 mice for each of three separate experiments). The statistical analysis was performed using Mann-
Whitney U test. * p,0.05, ** p,0.01 (infected halofuginone treated mice vs infected diluent treated mice). At day 4, 14 and 25 after infection, mice
were treated intravaginally with 10 mg of coelenterazine and imaged in the IVIS-200
TM imaging system under anesthesia using 2.5% isoflurane and
the vaginal lumen was washed with 150 ml of saline. (B) In vivo imaging of mice vaginally infected with Candida albicans cells (gLUC) and treated with
halofuginone or diluent. Images are representative of 5 out of 10 mice in two different experiments. (C) Dot plot of total photon emission from the
infected regions and dot plot of CFU in vaginal washes of mice (n=10) treated with halofuginone or diluent. The statistical analysis was performed
using non-parametric Mann-Whitney U test. The median is indicated by a straight line. Data are representative of one out of two independent
experiments with similar results. * p,0.05, ** p,0.01 (infected halofuginone treated mice vs infected diluent treated mice).
doi:10.1371/journal.pone.0022770.g006
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22770Figure 7. Effect of halofuginone treatment on vaginal b defensin production. Mice, under pseudo-estrus conditions, were twice infected
with 10
7 Candida albicans in vagina. Two days before and every two days after infection, mice were injected intraperitoneally with 5 mg/100 mlo f
halofuginone solution or diluent of halofuginone and were treated intravaginally with 10 pg of mouse rIL-17. At day 4, 8 and 14 after infection, mice
were treated intravaginally with 10 mg of coelenterazine and imaged in the IVIS-200
TM imaging system under anesthesia using 2.5% isoflurane. (A)
Dot plot of total photon emission from the infected regions and dot plot of CFU in vaginal washes. The statistical analysis was performed using non-
parametric Mann-Whitney U test. The median is indicated by a straight line. Data are representative of one out of two independent experiments with
similar results. After 4, 8, 14, 21, 28 days from challenge, the vaginal lumen was washed with 150 ml of saline and vaginal cells were recovered for b-
defensin analysis. (B) Mean of fluorescence MIF of b-defensin 1, b-defensin 2 and b-defensin 3 cells evaluated by FACS analysis. The vaginal cells
recovered by vaginal washes were stained with rabbit anti-mouse BD1, goat anti-mouse BD2 or goat anti-mouse BD3 and goat anti-rabbit TRIC
conjugate or rabbit anti-goat PE conjugate respectively. (C) Percentage of epithelial cells producing d b-defensin 2. Data are the mean6SD (n=8
mice, 4 mice for each of two separate experiments). Cells of vaginal washes were stained with FITC anti mouse pan-cytokeratin and goat anti-mouse
BD2 and rabbit anti-goat PE conjugate. Data are representative of one out of two independent experiments (total 8 mice). The statistical analysis was
performed using Mann-Whitney U test. * p,0.05, (infected halofuginone+IL-17 treated mice vs infected halofuginone treated mice).
doi:10.1371/journal.pone.0022770.g007
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production, the vaginal cells were counted by a hemocytometer,
left untreated or re-stimulated with 4610
6 heat inactivated C.
albicans, and incubated for 72 hours in cRPMI at 37uC. The
supernatants from the culture wells were treated with protease
inhibitors and stored at 220uC until the ELISA test, and the
vaginal cells were fixed with 4% of PFA.
Lymph node collection and processing
Vaginal draining lumbar lymph nodes were identified on the
posterior abdominal wall lateral to the inferior vena cava and
abdominal aorta, respectively. These lymph nodes were excised in
cRPMI medium, homogenized and counted with a hemocytom-
eter. To evaluate the cytokine production, the lymph node cells
(2610
6/ml) were left untreated or re-stimulated with 4610
6 heat
inactivated C. albicans for 72 hours in cRPMI at 37uC. The
supernatants from the culture wells were treated with protease
inhibitors and stored at 220uC until the ELISA test. The lymph
nodes cells were fixed with 4% of PFA.
Detection of intracellular and supernatant cytokines and
flow cytometry
The supernatants of vaginal washes, and vagina and lymph
node cell cultures, obtained from infected and non-infected mice
were assayed for the presence of IL-17 and IL-23 cytokines using
the enzyme-linked immunosorbent ELISA cytoset (eBioscience
and Biosource respectively). The analysis of surface molecules,
intracellular IL-17 and b-defensin contents of vaginal and lymph
node cells was performed by flow cytometry using standard
methodology for direct and indirect immunofluorescence. Briefly,
2610
5 cells treated with 10 mg/ml of Brefeldin A (Calbiochem) for
3 h, were incubated with PBS-S buffer (PBS with 0.1% of saponin)
for 45 minutes at 4uC with combinations of different antibodies.
For IL-17 detection, cells were labelled with rat anti mouse IL-17
PE conjugate (BD Pharmingen) and either rat anti mouse CD4-
FITC conjugate (Santa Cruz Biotechnology) or rat anti mouse Gr-
1 FITC conjugate; for b-defensin detection, rabbit anti mouse b-
defensin 1, goat anti mouse b-defensin 2 or goat anti mouse - b
defensin 3 (Santa Cruz Biotechnology), with goat anti-rabbit
TRIC conjugate or rabbit anti goat PE conjugate (Sigma-Aldrich),
were used. For epithelial cell labelling, a FITC conjugate antibody
anti-pan cytokeratin (Sigma) was used. Stained cells were washed
with PBS-S buffer, resuspended in fluorescent buffer (PBS with 1%
FBS and 0.5% NaN3) and analyzed using a FACScan cyto-
fluorimeter (Becton Dickinson, BD). The acquired data were
analyzed with CELLQuest software (BD).
Histological analysis
For histological evaluation, the mice were sacrificed, and the
vaginas were removed and immediately fixed in 10% (v/v) neutral
buffered formalin for 24 h. They were then dehydrated,
embedded in paraffin, sectioned into 3- to 4-mm-thick sections,
and stained with periodic acid-Schiff reagent.
Microscopic analysis of vaginal wash cells
The vaginal wash cells were cytospun onto a glass slide (4006g
for 7 min) and air dried for 1 h. Cells were then stained using Diff-
Quick staining and examined under a light microscope at a
magnification of 640. Neutrophils were identified by their
characteristic tri-lobar nucleus.
Halofuginone treatment
Mice were injected intraperitoneally with 5 mg/100 mlo r
10 mg/100 ml of a solution of halofuginone (obtained from
Collgard Biopharmaceuticals (Tel Aviv, Israel) or diluent, two
days before and every two days after infection. In parallel
experiments and at the same time as the halofuginone treatment,
mice were treated intravaginally with 10 ml (10 pg/mouse) of
recombinant mouse IL-17 (eBioscience).
Statistical analysis
Photon Flux emission, CFU counts, PMN count, IL-17, IL-23
and beta-defensin production were compared using the non-
parametric Mann–Whitney U-test. The alpha value was set at
0.05. The correlation between the Total Photons emitted and
CFU count in the vaginal wash was assessed with the Pearson’s
correlation test.
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